Maybe another Phase 3 is required?That would delay things for several more years. I wonder if this speculation is the reason for the sell off after the New York broker presentation??? What else would explain the drop? I read the presentation to mean that the FDA changes from 2013 meant that the first trial was sufficient for approval but I could be wrong even though I think that is what they were implying. If that is the case I hope that they start the trial work as soon as possible. Maybe another US financing will come with the consolidation? Then they would need more options to ensure insiders are not diluted but that is to be expected.